このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

除細動と信頼性のためのリード評価 (LEADR)

2026年10月13日 更新者:Medtronic Cardiac Rhythm and Heart Failure

The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead.

The LEADR LBBAP study is being conducted under the existing US FDA Investigational Device Exemption (IDE) for the Next Generation ICD Lead and is designed to confirm the safety and defibrillation efficacy of the Next Generation ICD Lead when placed in the LBBAP location in ICD and LOT-CRT patient population.

調査の概要

詳細な説明

The LEADR and LEADR LBBAP studies will enroll subjects who are indicated to receive an implantable single or dual chamber ICD, or CRT-D, and who meet all of the inclusion criteria and none of the exclusion criteria. Subjects will receive an investigational Next Generation ICD Lead. Subjects in the LEADR study will be followed for at least 18 months following Next Generation ICD Lead implantation in a septal (non-LBBAP) or apical implant location. Enrollment in the LEADR study has been completed (675 subjects enrolled). Subjects in the LEADR LBBAP study will be followed for at least 3 months (ICD-indicated subjects) or 6 months (CRT-indicated subjects) following Next Generation ICD Lead implantation in an LBBAP implant location. Enrollment in the LEADR LBBAP study has been completed (332 subjects enrolled).

研究の種類

介入

入学 (実際)

1007

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Huntsville、Alabama、アメリカ、35801
        • LEADR: Heart Center Research
    • California
      • Torrance、California、アメリカ、90505
        • LEADR LBBAP: Torrance Memorial Medical Center
    • Connecticut
      • Hartford、Connecticut、アメリカ、06106
        • LEADR: Hartford Hospital
    • Florida
      • Tampa、Florida、アメリカ、33606
        • LEADR: University of South Florida
    • Minnesota
      • Minneapolis、Minnesota、アメリカ、55407
        • LEADR & LEADR LBBAP: Minneapolis Heart Institute Foundation
    • Missouri
      • Kansas City、Missouri、アメリカ、64111
        • LEADR: Saint Luke's Mid America Heart Institute
      • St Louis、Missouri、アメリカ、63110
        • LEADR: Washington University School of Medicine
    • New Jersey
      • Voorhees Township、New Jersey、アメリカ、08034
        • LEADR: Lourdes Cardiology Services
    • New Mexico
      • Albuquerque、New Mexico、アメリカ、87108
        • LEADR: Presbyterian Heart Group
    • New York
      • Bay Shore、New York、アメリカ、11030
        • LEADR & LEADR LBBAP: South Shore University Hospital/Northwell Health
    • Ohio
      • Cincinnati、Ohio、アメリカ、45202
        • LEADR: TriHealth Hatton Research Institute
      • Cincinnati、Ohio、アメリカ、45219
        • LEADR LBBAP: The Christ Hospital
      • Cleveland、Ohio、アメリカ、44195
        • LEADR: Cleveland Clinic
      • Columbus、Ohio、アメリカ、43210
        • LEADR LBBAP: The Ohio State University Wexner Medical Center
    • Pennsylvania
      • Allentown、Pennsylvania、アメリカ、18103
        • LEADR: Lehigh Valley Hospital - Cedar Crest
      • Philadelphia、Pennsylvania、アメリカ、19104
        • LEADR: Hospital of the University of Pennsylvania
      • Wilkes-Barre、Pennsylvania、アメリカ、18711
        • LEADR LBBAP: Geisinger Wyoming Valley Medical Center
    • Tennessee
      • Nashville、Tennessee、アメリカ、37232
        • LEADR& LEADR LBBAP: Vanderbilt University medical Center
    • Texas
      • Austin、Texas、アメリカ、78705
        • LEADR: Texas Cardiac Arrhythmia Research Foundation
      • Fort Worth、Texas、アメリカ、76104
        • LEADR: Texas Health Fort Worth Hospital
    • Virginia
      • Charlottesville、Virginia、アメリカ、22903
        • LEADR & LEADR LBBAP: University of Virginia Medical Center
      • Richmond、Virginia、アメリカ、23298
        • LEADR & LEADR LBBAP: Virginia Commonwealth University Health System
    • Wisconsin
      • Milwaukee、Wisconsin、アメリカ、53215
        • LEADR LBBAP: Aurora St. Luke's Hospital
      • London、イギリス、W12 0HS
        • LEADR & LEADR LBBAP: Imperial College Healthcare NHS Trust - Hammersmith Hospital
      • Bergamo、イタリア、24127
        • LEADR: Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII
    • Limburg
      • Maastricht、Limburg、オランダ
        • LEADR LBBAP: Maastricht Universitair Medisch Centrum
      • Garran、オーストラリア、2605
        • LEADR &LEADR LBBAP: Canberra Hospital
    • Queensland
      • Chermside、Queensland、オーストラリア、4032
        • LEADR & LEADR LBBAP: The Prince Charles Hospital
    • South Australia
      • Ashford、South Australia、オーストラリア、8032
        • LEADR: Ashford Hospital
      • Norwood、South Australia、オーストラリア、5000
        • LEADR & LEADR LBBAP: Royal Adelaide
    • Mitterweg
      • Krems、Mitterweg、オーストリア、3500
        • LEADR: Universitätsklinikum Krems
    • Alberta
      • Calgary、Alberta、カナダ、T2N 4N1
        • LEADR: University of Calgary
    • Ontario
      • Newmarket、Ontario、カナダ、L3Y8C3
        • LEADR: Southlake Regional Health Centre
    • Quebec
      • Québec、Quebec、カナダ、G1V 4G5
        • LEADR & LEADR LBBAP: Institut Universitaire de Cardiologie et de Pneumologie de Quebec
    • Singapore
      • Singapore、Singapore、シンガポール
        • LEADR: Ng Teng Fong General Hospital
      • L'Hospitalet de Llobregat、スペイン
        • LEADR: Hospital Universitari Bellvitge
      • Valencia、スペイン、46026
        • LEADR: Hospital Universitario y Politécnico La Fe
    • Granada
      • Granada、Granada、スペイン、18014
        • LEADR LBBAP: Hospital Universitario Virgen de las Nieves
      • Belgrade、セルビア
        • LEADR: Klinicki Centar Srbije Pejsmejker centar
      • Copenhagen、デンマーク、2100
        • LEADR: Rigshospitalet
    • Bielefeld
      • Bielefeld、Bielefeld、ドイツ、33604
        • LEADR: Klinikum Bielefeld Kardiologie
      • La Tronche、フランス、38700
        • LEADR: Centre Hospitalier Universitaire de Grenoble - Site Nord
      • Montpellier、フランス、34960
        • LEADR LBBAP: OC Santé - Clinique du Millénaire
      • Rouen、フランス、76031
        • LEADR: CHU Hôpitaux de Rouen - Hôpital Charles Nicolle
    • Antwerp
      • Edegem、Antwerp、ベルギー、2650
        • LEADR LBBAP: Universitair Ziekenhuis Antwerpen
      • Carnaxide、ポルトガル、2790-134
        • LEADR: Centro Hospitalar de Lisboa Ocidental, E.P.E. Hospital de Santa Cruz Cardiology
      • Krakow、ポーランド
        • LEADR LBBAP: Szpital Uniwersytecki w Krakowie
      • Kuala Lumpur、マレーシア、50400
        • LEADR & LEADR LBBAP: Institut Jantung Negara - National Heart Institute
      • Chengdu、中国
        • LEADR & LEADR LBBAP: West China Hospital of Sichuan University
    • Shanxi
      • Taiyuan、Shanxi、中国、030000
        • LEADR: Shanxi Cardiovascular Hospital
    • Fukuoka
      • Kitakyushu、Fukuoka、日本、802-8555
        • LEADR & LEADR LBBAP: Kokura Memorial Hospital
    • Osaka
      • Suita、Osaka、日本、564-8565
        • LEADR & LEADR LBBAP: National Cerebral and Cardiovascular Center
    • Tokyo
      • Shinjuku-Ku、Tokyo、日本、162-8666
        • LEADR: Tokyo Women's Medical University Hospital
      • Hong Kong、香港
        • LEADR & LEADR LBBAP: Queen Mary Hospital
      • Lai Chi Kok、香港、999077
        • LEADR: Princess Margaret Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

12年歳以上 (子、大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

LEADR Inclusion Criteria:

  • Subject meets current clinical practice guidelines for implantation of ICD or CRT-D and will undergo one of the following:

    • de novo Medtronic CRT-D system implant
    • de novo Medtronic ICD system implant (single or dual chamber)
  • Subject has, per local law and requirements, the minimum age for autonomously signing an ICF (minimum age of 18 years)

  • Subject is willing to undergo implant defibrillation testing if requested.

  • Subject is geographically stable and willing and able to complete the study procedures and visits for the duration of the follow-up.

LEADR Exclusion Criteria:

  • Subject is unwilling or unable to personally provide Informed Consent.

  • Subject has contraindications for standard RV transvenous lead placement (e.g., mechanical right heart valve).

  • Subject is contraindicated for ≤1 mg dexamethasone acetate.

  • Subject has a life expectancy of less than 12 months

  • For subject undergoing defibrillation testing the following medical conditions exclude them:

    • Pre-existing or suspected pneumothorax during implant
    • Current intracardiac left atrial or left ventricular (LV) thrombus
    • Severe aortic stenosis
    • Severe proximal three-vessel or left main coronary artery disease without revascularization
    • Unstable angina
    • Ejection Fraction less than 25%
    • Recent stroke or transient ischemic attack (within the last 6 months)
    • Known inadequate external defibrillation
    • Any other known medical condition not listed that precludes their participation in the opinion of the investigator
  • Subject is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this study, without documented pre-approval from a Medtronic study manager.

  • Subject with any exclusion criteria as required by local law (e.g., age or other).

  • Pregnant women or breastfeeding women, or women of childbearing potential and who are not on a reliable form of birth regulation method or abstinence

  • Subject with an existing pacemaker (including transcatheter pacing system), ICD, or CRT device or leads

  • Subject with any evidence of active infection or undergoing treatment for an infection

  • Recent (or planned) cardiac surgery or stenting less than 1 month before implant

  • End stage renal disease

  • Subjects with NYHA IV classification

  • Subjects with a transplanted heart

  • Subjects with previously extracted leads

  • Subjects with Left Ventricular Assist Device

LEADR LBBAP Inclusion Criteria:

  • Subject meets current local clinical practice guidelines for implantation of ICD (single or dual chamber) or CRT-D system and will undergo one of the following:

    a) De novo Medtronic ICD system implant (single or dual chamber) or b) De novo Medtronic CRT-D system implant and is intended to also undergo LV lead implant (for patients indicated for CRT-D according to locally approved indications/indications)

  • Subject is 12 years of age or older and also is greater than 30 kg in weight at time of enrollment, has cardiac anatomy conducive to RV coil placement, and is allowed to participate in study per local law and requirements. Subjects from 12 years of age until adult also have a separate indication for pacing or CRT or are anticipated to develop one.

  • Subject provides written authorization and/or consent per institution and geographical requirements.

  • Subject is geographically stable and willing and able to complete the study procedures and visits for the duration of the follow-up

  • Subject is willing to undergo implant defibrillation testing if requested

LEADR LBBAP Exclusion Criteria:

  • Subject has contraindication for screw-in active fixation transvenous lead placement (e.g., mechanical right heart valve)

  • Subject is contraindicated for ≤1 mg dexamethasone acetate

  • Subject has a life expectancy of less than 12 months

  • For subject undergoing defibrillation testing the following medical conditions exclude them:

    • Pre-existing or suspected pneumothorax
    • Current intracardiac left atrial or LV thrombus
    • Severe aortic stenosis
    • Severe proximal three-vessel or left main coronary artery disease without revascularization
    • Unstable angina
    • Recent stroke or transient ischemic attack (within the last 6 months)
    • Known inadequate external defibrillation
    • Any other known medical condition not listed that precludes their participation in the opinion of the investigator
  • Subject is enrolled or planning to enroll in a concurrent clinical study that may confound the results of this study, without documented pre-approval from a Medtronic study manager

  • Subject is pregnant or breastfeeding, or subject is of childbearing potential and not on a reliable form of birth regulation method or abstinence

  • Subject with an existing pacemaker (including transvenous and transcatheter pacing system), ICD (transvenous) or CRT-D (transvenous) device or leads

  • Subject with previous subcutaneous ICD (S-ICD), extravascular ICD (EV ICD) or Implantable Cardiac Monitor explanted within 30 days before implant

  • Subject with any evidence of active bacterial infection or undergoing treatment for a bacterial infection within the last 30 days

  • Recent (or planned) cardiovascular intervention within 30 days before or after implant, such as cardiac surgery, cardiac ablation, Percutaneous Coronary Intervention (PCI), or temporary cardiac pacing for >12 hours

  • Subjects with end stage renal disease

  • Subjects with NYHA IV classification

  • Subjects with a transplanted heart or on the waiting list for a heart transplant

  • Subjects with previously extracted leads

  • Subjects with Left Ventricular Assist Device

  • Subjects that are vulnerable adults

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Intervention/Treatment (LEADR)

Patients will be implanted with a Next Generation ICD Lead and undergo required electrical testing

Required electrical testing for pacing, sensing, impedance and defibrillation will be completed

実験的:Intervention/Treatment (LEADR LBBAP)

Patients will be implanted with a Next Generation ICD Lead in the LBBAP location and undergo required electrical testing

Required electrical testing for pacing, sensing, impedance and defibrillation will be completed

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
LEADR: Estimate the Rate of Major Lead Complication-free Rate at 6 Months
時間枠:Implant to 6 Months

Subjects free of Next Generation ICD lead-related complication at 6 months post-implant.

Implant to 6 Months
LEADR: Percentage of Subjects Successfully Defibrillated at Implant With the Next Generation ICD Lead
時間枠:Day 1

Defibrillation testing will be completed in a subset of subjects at implant.

Day 1
LEADR LBBAP: Percentage of Subjects Successfully Defibrillated at Implant With the Next Generation ICD Lead
時間枠:Day 1

Defibrillation testing will be completed with the Next Generation ICD Lead in the LBBAP location in a subset of subjects at implant.

Day 1
LEADR LBBAP: The Lead-related Major Complication Rate at 3-months
時間枠:Implant to 3 Months

Subjects free of Next Generation ICD lead-related complication at 3 months post-implant.

Implant to 3 Months

二次結果の測定

結果測定
メジャーの説明
時間枠
LEADR: Estimate the Fracture-free Rate of the Next Generation ICD Lead
時間枠:up to 18 months

Subjects will be assessed at certain time points for Next Generation ICD lead fracture related to the Next Generation ICD lead.

up to 18 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:George Crossley, MD、Vanderbilt University (LEADR)
  • 主任研究者:Pugazhendhi Vijayaraman, MD、Geisinger Medical Center (LEADR LBBAP)

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年6月21日

一次修了 (実際)

2025年9月3日

研究の完了 (実際)

2025年11月6日

試験登録日

最初に提出

2021年4月21日

QC基準を満たした最初の提出物

2021年4月26日

最初の投稿 (実際)

2021年4月28日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月4日

QC基準を満たした最後の更新が送信されました

2026年10月13日

最終確認日

2025年4月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する